Pub Date : 2023-04-01DOI: 10.1080/14789450.2023.2215440
Maximilian Wolf, Kay Schallert, Luca Knipper, Albert Sickmann, Alexander Sczyrba, Dirk Benndorf, Robert Heyer
Introduction: Investigating the taxonomic and functional composition of human microbiomes can aid in the understanding of disease etiologies, diagnosis, and therapy monitoring for several diseases, including inflammatory bowel disease or obesity. One method for microbiome monitoring is metaproteomics, which assesses human and microbial proteins and thus enables the study of host-microbiome interactions. This advantage led to increased interest in metaproteome analyses and significant developments to introduce this method into a clinical context.
Areas covered: This review summarizes the recent progress from a technical side and an application-related point of view.
Expert opinion: Numerous publications imply the massive potential of metaproteomics to impact human health care. However, the key challenges of standardization and validation of experimental and bioinformatic workflows and accurate quantification methods must be overcome.
{"title":"Advances in the clinical use of metaproteomics.","authors":"Maximilian Wolf, Kay Schallert, Luca Knipper, Albert Sickmann, Alexander Sczyrba, Dirk Benndorf, Robert Heyer","doi":"10.1080/14789450.2023.2215440","DOIUrl":"https://doi.org/10.1080/14789450.2023.2215440","url":null,"abstract":"<p><strong>Introduction: </strong>Investigating the taxonomic and functional composition of human microbiomes can aid in the understanding of disease etiologies, diagnosis, and therapy monitoring for several diseases, including inflammatory bowel disease or obesity. One method for microbiome monitoring is metaproteomics, which assesses human and microbial proteins and thus enables the study of host-microbiome interactions. This advantage led to increased interest in metaproteome analyses and significant developments to introduce this method into a clinical context.</p><p><strong>Areas covered: </strong>This review summarizes the recent progress from a technical side and an application-related point of view.</p><p><strong>Expert opinion: </strong>Numerous publications imply the massive potential of metaproteomics to impact human health care. However, the key challenges of standardization and validation of experimental and bioinformatic workflows and accurate quantification methods must be overcome.</p>","PeriodicalId":50463,"journal":{"name":"Expert Review of Proteomics","volume":"20 4-6","pages":"71-86"},"PeriodicalIF":3.4,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9740800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Objectives: Hereditary transthyretin amyloidosis (ATTRv) is a rare, fatal, autosomal dominant disease with more than 140 mutations discovered. Three phenotypes of amyloid infiltration are neuropathy (ATTRv-PN), cardiopathy (ATTRv-CM), and neuropathy + cardiopathy (ATTRv-MIX). The lack of ATTR-specific biomarkers, difficulties in biopsy evidence, and limited known pathogenic mechanisms have made diagnosis difficult. Newly emerging noninvasive measures for monitoring progression and disease-modifying therapies have improved early diagnosis and patient management.
Methods: Our research applies the latest technology, Data-Independent Acquisition-Based Quantitative Proteomics (DIA), to reveal comprehensive plasma protein profiles in the natural history of Chinese patients with hereditary transthyretin amyloidosis (ATTRv). We analyzed differentially expressed proteins (DEPs) in three phenotypes (ATTRv-PN, ATTRv-CM, and ATTRv-MIX).
Results: Serum samples were collected from a total of 18 patients (6 ATTRv-PN, 5 ATTRv-CM, and 7 ATTRv-MIX patients) and 20 healthy participants as a control group. Combined with the results of the proteomic and bioinformatic analyses, we found 30 DEPs and protein interaction networks clustered in KRT family proteins and DSC3 between ATTRv-PN and the control, which were rich in the estrogen signaling pathway and the cell adhesion molecule (CAM) pathway.
Conclusion: This study demonstrates a global and significant proteomic profile in different stages of ATTRv.
{"title":"Data-independent acquisition mass spectrometry reveals comprehensive plasma protein profiles in the natural history of patients with hereditary transthyretin amyloidosis (ATTRv).","authors":"Shan He, XinYue He, RuoKai Pan, LuRong Pan, Xiaoying Lv, YuTong Jin, Yue Fan, YuTong Wang, Zhuang Tian, ShuYang Zhang","doi":"10.1080/14789450.2023.2195096","DOIUrl":"https://doi.org/10.1080/14789450.2023.2195096","url":null,"abstract":"<p><strong>Objectives: </strong>Hereditary transthyretin amyloidosis (ATTRv) is a rare, fatal, autosomal dominant disease with more than 140 mutations discovered. Three phenotypes of amyloid infiltration are neuropathy (ATTRv-PN), cardiopathy (ATTRv-CM), and neuropathy + cardiopathy (ATTRv-MIX). The lack of ATTR-specific biomarkers, difficulties in biopsy evidence, and limited known pathogenic mechanisms have made diagnosis difficult. Newly emerging noninvasive measures for monitoring progression and disease-modifying therapies have improved early diagnosis and patient management.</p><p><strong>Methods: </strong>Our research applies the latest technology, Data-Independent Acquisition-Based Quantitative Proteomics (DIA), to reveal comprehensive plasma protein profiles in the natural history of Chinese patients with hereditary transthyretin amyloidosis (ATTRv). We analyzed differentially expressed proteins (DEPs) in three phenotypes (ATTRv-PN, ATTRv-CM, and ATTRv-MIX).</p><p><strong>Results: </strong>Serum samples were collected from a total of 18 patients (6 ATTRv-PN, 5 ATTRv-CM, and 7 ATTRv-MIX patients) and 20 healthy participants as a control group. Combined with the results of the proteomic and bioinformatic analyses, we found 30 DEPs and protein interaction networks clustered in KRT family proteins and DSC3 between ATTRv-PN and the control, which were rich in the estrogen signaling pathway and the cell adhesion molecule (CAM) pathway.</p><p><strong>Conclusion: </strong>This study demonstrates a global and significant proteomic profile in different stages of ATTRv.</p>","PeriodicalId":50463,"journal":{"name":"Expert Review of Proteomics","volume":"20 1-3","pages":"57-69"},"PeriodicalIF":3.4,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9536233","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Introduction: The COVID-19 outbreak has put enormous pressure on the scientific community to detect infection rapidly, identify the status of disease severity, and provide an immediate vaccine/drug for the treatment. Relying on immunoassay and a real-time reverse transcription polymerase chain reaction (rRT-PCR) led to many false-negative and false-positive reports. Therefore, detecting biomarkers is an alternative and reliable approach for determining the infection, its severity, and disease progression. Recent advances in liquid chromatography and mass spectrometry (LC-MS/MS) enable the protein biomarkers even at low concentrations, thus facilitating clinicians to monitor the treatment in hospitals.
Areas covered: This review highlights the role of LC-MS/MS in identifying protein biomarkers and discusses the clinically significant protein biomarkers such as Serum amyloid A, Interleukin-6, C-Reactive Protein, Lactate dehydrogenase, D-dimer, cardiac troponin, ferritin, Alanine transaminase, Aspartate transaminase, gelsolin and galectin-3-binding protein in COVID-19, and their analysis by LC-MS/MS in the early stage.
Expert opinion: Clinical doctors monitor significant biomarkers to understand, stratify, and treat patients according to disease severity. Knowledge of clinically significant COVID-19 protein biomarkers is critical not only for COVID-19 caused by the coronavirus but also to prepare us for future pandemics of other diseases in detecting by LC-MS/MS at the early stages.
{"title":"LC-MS/MS: A sensitive and selective analytical technique to detect COVID-19 protein biomarkers in the early disease stage.","authors":"Siva Nageswara Rao Gajula, Ankita Sahebrao Khairnar, Pallavi Jock, Nikita Kumari, Kendre Pratima, Vijay Munjal, Pavan Kalan, Rajesh Sonti","doi":"10.1080/14789450.2023.2191845","DOIUrl":"https://doi.org/10.1080/14789450.2023.2191845","url":null,"abstract":"<p><strong>Introduction: </strong>The COVID-19 outbreak has put enormous pressure on the scientific community to detect infection rapidly, identify the status of disease severity, and provide an immediate vaccine/drug for the treatment. Relying on immunoassay and a real-time reverse transcription polymerase chain reaction (rRT-PCR) led to many false-negative and false-positive reports. Therefore, detecting biomarkers is an alternative and reliable approach for determining the infection, its severity, and disease progression. Recent advances in liquid chromatography and mass spectrometry (LC-MS/MS) enable the protein biomarkers even at low concentrations, thus facilitating clinicians to monitor the treatment in hospitals.</p><p><strong>Areas covered: </strong>This review highlights the role of LC-MS/MS in identifying protein biomarkers and discusses the clinically significant protein biomarkers such as Serum amyloid A, Interleukin-6, C-Reactive Protein, Lactate dehydrogenase, D-dimer, cardiac troponin, ferritin, Alanine transaminase, Aspartate transaminase, gelsolin and galectin-3-binding protein in COVID-19, and their analysis by LC-MS/MS in the early stage.</p><p><strong>Expert opinion: </strong>Clinical doctors monitor significant biomarkers to understand, stratify, and treat patients according to disease severity. Knowledge of clinically significant COVID-19 protein biomarkers is critical not only for COVID-19 caused by the coronavirus but also to prepare us for future pandemics of other diseases in detecting by LC-MS/MS at the early stages.</p>","PeriodicalId":50463,"journal":{"name":"Expert Review of Proteomics","volume":"20 1-3","pages":"5-18"},"PeriodicalIF":3.4,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9831802","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01DOI: 10.1080/14789450.2023.2210764
Mika Alexia Miyazaki, Raquel Lozano Guilharducci, Paula Intasqui, Ricardo Pimenta Bertolla
Introduction: Spermatozoa are highly specialized cells with unique morphology. In addition, spermatozoa lose a considerable amount of cytoplasm during spermiogenesis, when they also compact their DNA, resulting in a transcriptionally quiescent cell. Throughout the male reproductive tract, sperm will acquire proteins that enable them to interact with the female reproductive tract. After ejaculation, proteins undergo post-translational modifications for sperm to capacitate, hyperactivate, and fertilize the oocyte. Many proteins have been identified as predictors of male infertility and also investigated in diseases that compromise reproductive potential.
Areas covered: In this review, we proposed to summarize the recent findings about the sperm proteome and how they affect sperm structure, function, and fertility. A literature search was performed using PubMed and Google Scholar databases within the past 5 years until August 2022.
Expert opinion: Sperm function depends on protein abundance, conformation, and PTMs; understanding the sperm proteome may help to identify pathways essential to fertility, even making it possible to unravel the mechanisms involved in idiopathic infertility. In addition, proteomics evaluation offers knowledge regarding alterations that compromise the male reproductive potential.
{"title":"Mapping the human sperm proteome - novel insights into reproductive research.","authors":"Mika Alexia Miyazaki, Raquel Lozano Guilharducci, Paula Intasqui, Ricardo Pimenta Bertolla","doi":"10.1080/14789450.2023.2210764","DOIUrl":"https://doi.org/10.1080/14789450.2023.2210764","url":null,"abstract":"<p><strong>Introduction: </strong>Spermatozoa are highly specialized cells with unique morphology. In addition, spermatozoa lose a considerable amount of cytoplasm during spermiogenesis, when they also compact their DNA, resulting in a transcriptionally quiescent cell. Throughout the male reproductive tract, sperm will acquire proteins that enable them to interact with the female reproductive tract. After ejaculation, proteins undergo post-translational modifications for sperm to capacitate, hyperactivate, and fertilize the oocyte. Many proteins have been identified as predictors of male infertility and also investigated in diseases that compromise reproductive potential.</p><p><strong>Areas covered: </strong>In this review, we proposed to summarize the recent findings about the sperm proteome and how they affect sperm structure, function, and fertility. A literature search was performed using PubMed and Google Scholar databases within the past 5 years until August 2022.</p><p><strong>Expert opinion: </strong>Sperm function depends on protein abundance, conformation, and PTMs; understanding the sperm proteome may help to identify pathways essential to fertility, even making it possible to unravel the mechanisms involved in idiopathic infertility. In addition, proteomics evaluation offers knowledge regarding alterations that compromise the male reproductive potential.</p>","PeriodicalId":50463,"journal":{"name":"Expert Review of Proteomics","volume":"20 1-3","pages":"19-45"},"PeriodicalIF":3.4,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9479004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01DOI: 10.1080/14789450.2023.2203390
Anh M Tran-Huynh, Matthew V Holt, Meenakshi Anurag
Nearly, 45,000 women are estimated to die from breast cancer in 2022 in the US alone [1,2]. Breast cancer displays high heterogeneity with a wide spectrum of clinical, pathological, and molecular features, which makes it challenging for successful therapy. As we are inching toward the era of personalized medicine, advances in subtyping breast tumors have impacted prognosis and therapeutics [3]. Proteogenomics, which is an integrative profiling approach utilizing DNA, RNA, and protein data, has clearly played a critical role in illuminating the complexity of breast tumor biology, and predicting treatment response. Since DNA and RNA sequencing has gained momentum in breast cancer clinical assays including targeted mutation panel or RNA-based PAM50-based intrinsic subtyping, it is important to highlight the capabilities of integrative approaches rather than focusing on proteomics in silo. The complementation of proteomics platform provides an opportunity not just for biomarker assessment but also better quantification of targetable proteins and pathways. This methodological advancement provides an elaborate molecular landscape of breast tumors in light of treatment response and toxicity [4,5].
{"title":"How valuable can proteogenomics be in clinical breast cancer research?","authors":"Anh M Tran-Huynh, Matthew V Holt, Meenakshi Anurag","doi":"10.1080/14789450.2023.2203390","DOIUrl":"https://doi.org/10.1080/14789450.2023.2203390","url":null,"abstract":"Nearly, 45,000 women are estimated to die from breast cancer in 2022 in the US alone [1,2]. Breast cancer displays high heterogeneity with a wide spectrum of clinical, pathological, and molecular features, which makes it challenging for successful therapy. As we are inching toward the era of personalized medicine, advances in subtyping breast tumors have impacted prognosis and therapeutics [3]. Proteogenomics, which is an integrative profiling approach utilizing DNA, RNA, and protein data, has clearly played a critical role in illuminating the complexity of breast tumor biology, and predicting treatment response. Since DNA and RNA sequencing has gained momentum in breast cancer clinical assays including targeted mutation panel or RNA-based PAM50-based intrinsic subtyping, it is important to highlight the capabilities of integrative approaches rather than focusing on proteomics in silo. The complementation of proteomics platform provides an opportunity not just for biomarker assessment but also better quantification of targetable proteins and pathways. This methodological advancement provides an elaborate molecular landscape of breast tumors in light of treatment response and toxicity [4,5].","PeriodicalId":50463,"journal":{"name":"Expert Review of Proteomics","volume":"20 1-3","pages":"1-4"},"PeriodicalIF":3.4,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9849746","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Introduction: The lysosome is the main degradative organelle of almost all mammalian cells, fulfilling important functions in macromolecule recycling, metabolism, and signaling. Lysosomal dysfunction is connected to a continuously growing number of pathologic conditions, and lysosomal proteins present potential biomarkers for a variety of diseases. Therefore, there is an increasing interest in their analysis in patient samples.
Areas covered: We provide an overview of OMICs studies which identified lysosomal proteins as potential biomarkers for pathological conditions, covering proteomics, genomics, and transcriptomics approaches, identified through PubMed searches. With respect to discovery proteomics analyses, mainly lysosomal luminal and associated proteins were detected, while membrane proteins were found less frequently. Comprehensive coverage of the lysosomal proteome was only achieved by ultra-deep-coverage studies, but targeted approaches allowed for the reproducible quantification of lysosomal proteins in diverse sample types.
Expert opinion: The low abundance of lysosomal proteins complicates their reproducible analysis in patient samples. Whole proteome shotgun analyses fail in many instances to cover the lysosomal proteome, which is due to under-sampling and/or a lack of sensitivity. With the current state of the art, targeted proteomics assays provide the best performance for the characterization of lysosomal proteins in patient samples.
{"title":"Updates on the study of lysosomal protein dynamics: possibilities for the clinic.","authors":"Dhriti Arora, Yannic Hackenberg, Jiaran Li, Dominic Winter","doi":"10.1080/14789450.2023.2190515","DOIUrl":"https://doi.org/10.1080/14789450.2023.2190515","url":null,"abstract":"<p><strong>Introduction: </strong>The lysosome is the main degradative organelle of almost all mammalian cells, fulfilling important functions in macromolecule recycling, metabolism, and signaling. Lysosomal dysfunction is connected to a continuously growing number of pathologic conditions, and lysosomal proteins present potential biomarkers for a variety of diseases. Therefore, there is an increasing interest in their analysis in patient samples.</p><p><strong>Areas covered: </strong>We provide an overview of OMICs studies which identified lysosomal proteins as potential biomarkers for pathological conditions, covering proteomics, genomics, and transcriptomics approaches, identified through PubMed searches. With respect to discovery proteomics analyses, mainly lysosomal luminal and associated proteins were detected, while membrane proteins were found less frequently. Comprehensive coverage of the lysosomal proteome was only achieved by ultra-deep-coverage studies, but targeted approaches allowed for the reproducible quantification of lysosomal proteins in diverse sample types.</p><p><strong>Expert opinion: </strong>The low abundance of lysosomal proteins complicates their reproducible analysis in patient samples. Whole proteome shotgun analyses fail in many instances to cover the lysosomal proteome, which is due to under-sampling and/or a lack of sensitivity. With the current state of the art, targeted proteomics assays provide the best performance for the characterization of lysosomal proteins in patient samples.</p>","PeriodicalId":50463,"journal":{"name":"Expert Review of Proteomics","volume":"20 1-3","pages":"47-55"},"PeriodicalIF":3.4,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9831804","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-07-01Epub Date: 2022-12-26DOI: 10.1080/14789450.2022.2160324
Yasset Perez-Riverol
Introduction: The creation of ProteomeXchange data workflows in 2012 transformed the field of proteomics, consisting of the standardization of data submission and dissemination and enabling the widespread reanalysis of public MS proteomics data worldwide. ProteomeXchange has triggered a growing trend toward public dissemination of proteomics data, facilitating the assessment, reuse, comparative analyses, and extraction of new findings from public datasets. By 2022, the consortium is integrated by PRIDE, PeptideAtlas, MassIVE, jPOST, iProX, and Panorama Public.
Areas covered: Here, we review and discuss the current ecosystem of resources, guidelines, and file formats for proteomics data dissemination and reanalysis. Special attention is drawn to new exciting quantitative and post-translational modification-oriented resources. The challenges and future directions on data depositions including the lack of metadata and cloud-based and high-performance software solutions for fast and reproducible reanalysis of the available data are discussed.
Expert opinion: The success of ProteomeXchange and the amount of proteomics data available in the public domain have triggered the creation and/or growth of other protein knowledgebase resources. Data reuse is a leading, active, and evolving field; supporting the creation of new formats, tools, and workflows to rediscover and reshape the public proteomics data.
简介2012年,ProteomeXchange数据工作流的创建改变了蛋白质组学领域,包括数据提交和传播的标准化,以及全球范围内公共质谱蛋白质组学数据的广泛再分析。ProteomeXchange 引发了蛋白质组学数据公开传播的趋势,促进了公共数据集的评估、再利用、比较分析和新发现的提取。到 2022 年,该联盟将由 PRIDE、PeptideAtlas、MassIVE、jPOST、iProX 和 Panorama Public 整合而成:在此,我们回顾并讨论了当前用于蛋白质组学数据传播和再分析的资源、指南和文件格式生态系统。我们将特别关注以定量和翻译后修饰为导向的新资源。此外,还讨论了数据沉积所面临的挑战和未来发展方向,包括缺乏元数据和基于云的高性能软件解决方案,无法对现有数据进行快速、可重现的再分析:ProteomeXchange 的成功以及公共领域中可获得的大量蛋白质组学数据引发了其他蛋白质知识库资源的创建和/或增长。数据再利用是一个领先、活跃和不断发展的领域;它支持创建新的格式、工具和工作流程,以重新发现和重塑公共蛋白质组学数据。
{"title":"Proteomic repository data submission, dissemination, and reuse: key messages.","authors":"Yasset Perez-Riverol","doi":"10.1080/14789450.2022.2160324","DOIUrl":"10.1080/14789450.2022.2160324","url":null,"abstract":"<p><strong>Introduction: </strong>The creation of ProteomeXchange data workflows in 2012 transformed the field of proteomics, consisting of the standardization of data submission and dissemination and enabling the widespread reanalysis of public MS proteomics data worldwide. ProteomeXchange has triggered a growing trend toward public dissemination of proteomics data, facilitating the assessment, reuse, comparative analyses, and extraction of new findings from public datasets. By 2022, the consortium is integrated by PRIDE, PeptideAtlas, MassIVE, jPOST, iProX, and Panorama Public.</p><p><strong>Areas covered: </strong>Here, we review and discuss the current ecosystem of resources, guidelines, and file formats for proteomics data dissemination and reanalysis. Special attention is drawn to new exciting quantitative and post-translational modification-oriented resources. The challenges and future directions on data depositions including the lack of metadata and cloud-based and high-performance software solutions for fast and reproducible reanalysis of the available data are discussed.</p><p><strong>Expert opinion: </strong>The success of ProteomeXchange and the amount of proteomics data available in the public domain have triggered the creation and/or growth of other protein knowledgebase resources. Data reuse is a leading, active, and evolving field; supporting the creation of new formats, tools, and workflows to rediscover and reshape the public proteomics data.</p>","PeriodicalId":50463,"journal":{"name":"Expert Review of Proteomics","volume":"19 7-12","pages":"297-310"},"PeriodicalIF":3.8,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7614296/pdf/EMS159053.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9174208","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-07-01DOI: 10.1080/14789450.2023.2174851
Juan Manuel Sacnun, Rebecca Herzog, Klaus Kratochwill
Introduction: The peritoneum, pleura, and pericardium are yet understudied multicellular systems where mesothelial cells (MCs) and endothelial cells (ECs) are in close proximity. Crosstalk between these cell types likely plays role in molecular transport, immunological reactions, and metabolic processes in health, disease, and therapeutic intervention.
Areas covered: In this review, we discuss recent proteomic efforts to characterize the crosstalk between MC and EC. We describe the proteomic methods necessary for investigation of crosstalk between MC and EC, as well as the in-vitro models that can be employed. Potential experimental approaches range from conditioned medium, via co-culture on semi-permeable membranes, to 3D cell culture based organoid models. While the biological and clinical relevance of the models may increase with their ability to mimic close cell communication, the practicality of these complex experiments corresponds vice versa, making standardization more difficult and expensive.
Expert opinion: Currently, data and reports on mesothelial-to-endothelial crosstalk are still very scarce. In our opinion, the in-vitro model using semi-permeable cell culture inserts will allow to establish a basic understanding of cellular crosstalk that may occur between those cell types. Later-on, more sophisticated 3D cell cultures may be better able to simulate the transport dynamics within the peritoneal membrane.
{"title":"Proteomic study of mesothelial and endothelial cross-talk: key lessons.","authors":"Juan Manuel Sacnun, Rebecca Herzog, Klaus Kratochwill","doi":"10.1080/14789450.2023.2174851","DOIUrl":"https://doi.org/10.1080/14789450.2023.2174851","url":null,"abstract":"<p><strong>Introduction: </strong>The peritoneum, pleura, and pericardium are yet understudied multicellular systems where mesothelial cells (MCs) and endothelial cells (ECs) are in close proximity. Crosstalk between these cell types likely plays role in molecular transport, immunological reactions, and metabolic processes in health, disease, and therapeutic intervention.</p><p><strong>Areas covered: </strong>In this review, we discuss recent proteomic efforts to characterize the crosstalk between MC and EC. We describe the proteomic methods necessary for investigation of crosstalk between MC and EC, as well as the in-vitro models that can be employed. Potential experimental approaches range from conditioned medium, via co-culture on semi-permeable membranes, to 3D cell culture based organoid models. While the biological and clinical relevance of the models may increase with their ability to mimic close cell communication, the practicality of these complex experiments corresponds vice versa, making standardization more difficult and expensive.</p><p><strong>Expert opinion: </strong>Currently, data and reports on mesothelial-to-endothelial crosstalk are still very scarce. In our opinion, the in-vitro model using semi-permeable cell culture inserts will allow to establish a basic understanding of cellular crosstalk that may occur between those cell types. Later-on, more sophisticated 3D cell cultures may be better able to simulate the transport dynamics within the peritoneal membrane.</p>","PeriodicalId":50463,"journal":{"name":"Expert Review of Proteomics","volume":"19 7-12","pages":"289-296"},"PeriodicalIF":3.4,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9488427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-07-01DOI: 10.1080/14789450.2023.2176755
Vladimir N Uversky
Since at the molecular level, almost all physiological processes are defined by the specific activities of specific proteins or protein groups, dysfunction and deregulation of these proteins are linked to the pathogenesis of various maladies. Therefore, to get to the roots of the pathological processes and find appropriate cure for the related diseases, one should clearly know the connections between protein-centric physiology and pathology. This logic represents premises of the medical protein science, where one is looking for the connections between the ‘right’ protein structure and normal function to understand how dysfunction can be linked back to the ‘wrong’ structure and assuming that fixing such ‘wrong’ structure can serve as a means to restore a normal function and therefore cure a disease. Even though mutations in a gene encoding a culprit protein represent the major reason for this protein to gain ‘wrong’ structure, dysfunctionality can also be caused by the distortion of any means from a very broad arsenal of cellular proteostasis-related mechanisms evolved to control and regulate protein folding, structure, and function. Although for the first time, proteins were described by the Dutch chemist Gerardus Johannes Mulder (1802–1880) as enormous molecules, with empirical formula for fibrin and egg albumin being C400H620N100O120P1S1, in his 1838 paper ‘On the composition of some animal substances’ first published in French [1] and translated to German in 1839 [2], they gained serious attention of researchers only after their polypeptide nature discovered independently in 1902 by a German chemist Hermann Emil Louis Fischer (1852–1919) [3] and an early protein scientist Franz Hofmeister (1850–1922) [4] was connected to the enzymatic activity by an American chemist, James B. Sumner (1887–1955), who, in 1926, showed that the enzyme urease is a protein that can be isolated and crystallized [5]. Curiously, as early as in 1894, enzymatic activity was proposed by Emil Fischer to follow his classical ‘lock-and-key’ model [6]. This concept was eventually elaborated into the famous protein structure-function paradigm, where the amino acid sequence determines a uniquely folded 3D structure that can be visualized in the crystalline state and that, in turn, defines the unique protein function [7]. As a result, in most of the almost 185 years of their history (and definitely since 1894), proteins were equated to enzymes, being considered as biological catalysts, while many other functions of these biological macromolecules and their intriguing potential to be multifunctional were mostly ignored.
{"title":"Rebellion of the deregulated regulators: What is the clinical relevance of studying intrinsically disordered proteins?","authors":"Vladimir N Uversky","doi":"10.1080/14789450.2023.2176755","DOIUrl":"https://doi.org/10.1080/14789450.2023.2176755","url":null,"abstract":"Since at the molecular level, almost all physiological processes are defined by the specific activities of specific proteins or protein groups, dysfunction and deregulation of these proteins are linked to the pathogenesis of various maladies. Therefore, to get to the roots of the pathological processes and find appropriate cure for the related diseases, one should clearly know the connections between protein-centric physiology and pathology. This logic represents premises of the medical protein science, where one is looking for the connections between the ‘right’ protein structure and normal function to understand how dysfunction can be linked back to the ‘wrong’ structure and assuming that fixing such ‘wrong’ structure can serve as a means to restore a normal function and therefore cure a disease. Even though mutations in a gene encoding a culprit protein represent the major reason for this protein to gain ‘wrong’ structure, dysfunctionality can also be caused by the distortion of any means from a very broad arsenal of cellular proteostasis-related mechanisms evolved to control and regulate protein folding, structure, and function. Although for the first time, proteins were described by the Dutch chemist Gerardus Johannes Mulder (1802–1880) as enormous molecules, with empirical formula for fibrin and egg albumin being C400H620N100O120P1S1, in his 1838 paper ‘On the composition of some animal substances’ first published in French [1] and translated to German in 1839 [2], they gained serious attention of researchers only after their polypeptide nature discovered independently in 1902 by a German chemist Hermann Emil Louis Fischer (1852–1919) [3] and an early protein scientist Franz Hofmeister (1850–1922) [4] was connected to the enzymatic activity by an American chemist, James B. Sumner (1887–1955), who, in 1926, showed that the enzyme urease is a protein that can be isolated and crystallized [5]. Curiously, as early as in 1894, enzymatic activity was proposed by Emil Fischer to follow his classical ‘lock-and-key’ model [6]. This concept was eventually elaborated into the famous protein structure-function paradigm, where the amino acid sequence determines a uniquely folded 3D structure that can be visualized in the crystalline state and that, in turn, defines the unique protein function [7]. As a result, in most of the almost 185 years of their history (and definitely since 1894), proteins were equated to enzymes, being considered as biological catalysts, while many other functions of these biological macromolecules and their intriguing potential to be multifunctional were mostly ignored.","PeriodicalId":50463,"journal":{"name":"Expert Review of Proteomics","volume":"19 7-12","pages":"279-282"},"PeriodicalIF":3.4,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9120103","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-07-01DOI: 10.1080/14789450.2023.2176756
Xiaoyin Zeng, Yanting Lan, Jing Xiao, Longbo Hu, Long Tan, Mengdi Liang, Xufei Wang, Shaohua Lu, Tao Peng, Fei Long
Introduction: Chronic obstructive pulmonary disease (COPD) was the third leading cause of global death in 2019, causing a huge economic burden to society. Therefore, it is urgent to identify specific phenotypes of COPD patients through early detection, and to promptly treat exacerbations. The field of phosphoproteomics has been a massive advancement, compelled by the developments in mass spectrometry, enrichment strategies, algorithms, and tools. Modern mass spectrometry-based phosphoproteomics allows understanding of disease pathobiology, biomarker discovery, and predicting new therapeutic modalities.
Areas covered: In this article, we present an overview of phosphoproteomic research and strategies for enrichment and fractionation of phosphopeptides, identification of phosphorylation sites, chromatographic separation and mass spectrometry detection strategies, and the potential application of phosphorylated proteomic analysis in the diagnosis, treatment, and prognosis of COPD disease.
Expert opinion: The role of phosphoproteomics in COPD is critical for understanding disease pathobiology, identifying potential biomarkers, and predicting new therapeutic approaches. However, the complexity of COPD requires the more comprehensive understanding that can be achieved through integrated multi-omics studies. Phosphoproteomics, as a part of these multi-omics approaches, can provide valuable insights into the underlying mechanisms of COPD.
{"title":"Advances in phosphoproteomics and its application to COPD.","authors":"Xiaoyin Zeng, Yanting Lan, Jing Xiao, Longbo Hu, Long Tan, Mengdi Liang, Xufei Wang, Shaohua Lu, Tao Peng, Fei Long","doi":"10.1080/14789450.2023.2176756","DOIUrl":"https://doi.org/10.1080/14789450.2023.2176756","url":null,"abstract":"<p><strong>Introduction: </strong>Chronic obstructive pulmonary disease (COPD) was the third leading cause of global death in 2019, causing a huge economic burden to society. Therefore, it is urgent to identify specific phenotypes of COPD patients through early detection, and to promptly treat exacerbations. The field of phosphoproteomics has been a massive advancement, compelled by the developments in mass spectrometry, enrichment strategies, algorithms, and tools. Modern mass spectrometry-based phosphoproteomics allows understanding of disease pathobiology, biomarker discovery, and predicting new therapeutic modalities.</p><p><strong>Areas covered: </strong>In this article, we present an overview of phosphoproteomic research and strategies for enrichment and fractionation of phosphopeptides, identification of phosphorylation sites, chromatographic separation and mass spectrometry detection strategies, and the potential application of phosphorylated proteomic analysis in the diagnosis, treatment, and prognosis of COPD disease.</p><p><strong>Expert opinion: </strong>The role of phosphoproteomics in COPD is critical for understanding disease pathobiology, identifying potential biomarkers, and predicting new therapeutic approaches. However, the complexity of COPD requires the more comprehensive understanding that can be achieved through integrated multi-omics studies. Phosphoproteomics, as a part of these multi-omics approaches, can provide valuable insights into the underlying mechanisms of COPD.</p>","PeriodicalId":50463,"journal":{"name":"Expert Review of Proteomics","volume":"19 7-12","pages":"311-324"},"PeriodicalIF":3.4,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9118955","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}